조용균

진료분야

바이러스성 간염, 급만성간질환, 간암, 간경화, 지방간

진료일정

  • 외래진료
  • 국내 학회
  • 국외 학회
  • 강의
  • 휴가
  • 기타
구분 월 화 수 목 금 토
오전
오후
온라인 진료예약 바로가기

학력 및 경력

한양대학교 의과대학 박사
한양대학교 의과대학


성균관대학교 의과대학 내과학 교수
성균관대학교 의과대학 강북삼성병원 건강의학부원장
성균관대학교 의과대학 강북삼성병원 소화기암센터장
성균관대학교 의과대학 강북삼성병원 교육인재개발실장, 의대학생교육실장
성균관대학교 의과대학 강북삼성병원 소화기내과 과장, 내과 주임과장
성균관대학교 의과대학 강북삼성병원 의학정보실장, 의학연구소장, 기획실부실장
성균관대학교 의과대학 강북삼성병원 입원의학과장
성균관대학교 의과대학 강북삼성병원 건강의학부원장
미국 국립보건원(NIH) 국립암센터(NCI) 교환교수
아시아 태평양 간학회 조직위원
대한간학회 지방간 연구회 회장
대한간학회 간경변증 가이드라인 개정위원
대한간학회 지방간 가이드라인 개정 위원장
대한간학회 보험위원, 홍보위원, 학술위원, 간행위원
대한소화기학회 편집위원회 간사
대한간학회 전산정보위원회 이사

학회 활동

아시아 태평양 간학회 조직위원
대한간학회 지방간 연구회 회장
대한간학회 간경변증 가이드라인 개정위원
대한간학회 지방간 가이드라인 개정 위원장
대한간학회 보험위원, 홍보위원, 학술위원, 간행위원
대한소화기학회 편집위원회 간사
대한간학회 전산정보위원회 이사

대표 논문

[국외]
Isolated Hepatitis B Core Antibody Positivity and Long-Term Liver-Related Mortality in Korea: A Cohort Study.
Sohn W, Chang Y, Cho YK, Hong YS, Ryu S.
Am J Gastroenterol. 2023 Jan 1; 118(1)

Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients.
Yim HJ, Kim JH, Cho YK, Kweon YO, Cho HC, Hwang JS, Lee C, Koh MS, Baek YH, Park YM, Lee JH, Kim SU, Kang MK, Park NH, Lee JS, Chon YE, Cheon GJ, Chae HB, Sohn JH, Lim YS.
Drug Des Devel Ther. 2022; 16

Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort.
Hsu YC, Jun DW, Peng CY, Yeh ML, Trinh H, Wong GL, Kim SE, Chen CH, Oh H, Lin CH, Trinh L, Wong VW, Yoon E, Ahn SB, Huang D, Cho YK, Jeong JY, Jeong SW, Kim HS, Xie Q, Liu L, Riveiro-Barciela M, Tsai PC, Accarino EV, Toyoda H, Enomoto M, Preda C, Marciano S, Hoang J, Huang CF, Kozuka R, Yasuda S, Istratescu D, Lee DH, Su JY, Huang YT, Huang JF, Dai CY, Chuang WL, Yuen MF, Gadano A, Cheung R, Lim SG, Buti M, Yu ML, Nguyen MH.
Hepatol Int. 2022 Dec; 16(6)

Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B.
Jang H, Yoon JS, Park SY, Lee HA, Jang MJ, Kim SU, Sinn DH, Seo YS, Kim HY, Kim SE, Jun DW, Yoon EL, Sohn JH, Ahn SB, Shim JJ, Jeong SW, Cho YK, Kim HS, Nam JY, Lee YB, Kim YJ, Yoon JH, Zoulim F, Lampertico P, Dalekos GN, Idilman R, Sypsa V, Berg T, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Janssen H, Papatheodoridis GV, Lee JH.
Clin Gastroenterol Hepatol. 2022 Jun; 20(6)

Risk of liver fibrosis in patients with prediabetes and diabetes mellitus.
Park J, Kwon HJ, Sohn W, Cho JY, Park SJ, Chang Y, Ryu S, Kim BI, Cho YK.
PLOS ONE. 2022; 17(6)

Liver Fibrosis in Asians With Metabolic Dysfunction-Associated Fatty Liver Disease.
Sohn W, Kwon HJ, Chang Y, Ryu S, Cho YK.
Clin Gastroenterol Hepatol. 2022 May; 20(5)

A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients.
Kim HJ, Kim JH, Yeon JE, Seo YS, Jang JW, Cho YK, Jang BK, Han BH, Lee C, Lee JH, Yoon JH, Kim KM, Kim MY, Kim DY, Park NH, Cho EY, Lee JS, Lee JW, Kim IH, Song BC, Lee BS, Kwon OS.
J Korean Med Sci. 2022 Mar 21; 37(11)

An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.
Kim HY, Lampertico P, Nam JY, Lee HC, Kim SU, Sinn DH, Seo YS, Lee HA, Park SY, Lim YS, Jang ES, Yoon EL, Kim HS, Kim SE, Ahn SB, Shim JJ, Jeong SW, Jung YJ, Sohn JH, Cho YK, Jun DW, Dalekos GN, Idilman R, Sypsa V, Berg T, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Janssen HLA, Jang MJ, Lee YB, Kim YJ, Yoon JH, Papatheodoridis GV, Lee JH.
J Hepatol. 2022 Feb; 76(2)

Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. Mak LY, Hoang J, Jun DW, Chen CH, Peng CY, Yeh ML, Kim SE, Huang DQ, Jeong JY, Yoon E, Oh H, Tsai PC, Huang CF, Ahn SB, Trinh H, Xie Q, Wong GLH, Enomoto M, Shim JJ, Lee DH, Liu L, Kozuka R, Cho YK, Jeong SW, Kim HS, Trinh L, Dao A, Huang R, Hui RW, Tsui V, Quek S, Khine H, Ogawa E, Dai CY, Huang JF, Cheung R, Wu C, Chuang WL, Lim SG, Yu ML, Yuen MF, Nguyen MH.
Hepatol Int. 2022 Feb; 16(1)

On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients.
Huang CF, Jang TY, Jun DW, Ahn SB, An J, Enomoto M, Takahashi H, Ogawa E, Yoon E, Jeong SW, Shim JJ, Jeong JY, Kim SE, Oh H, Kim HS, Cho YK, Kozuka R, Inoue K, Cheung KS, Mak LY, Huang JF, Dai CY, Yuen MF, Nguyen MH, Yu ML.
Liver Int.2022 Jan; 42(1)

A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients.
Kim HJ, Kim JH, Yeon JE, Seo YS, Jang JW, Cho YK, Jang BK, Han BH, Lee C, Lee JH, Yoon JH, Kim KM, Kim MY, Kim DY, Park NH, Cho EY, Lee JS, Lee JW, Kim IH, Song BC, Lee BS, Kwon OS
J Korean Med Sci. 2022 Mar 21; 37(11)

An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.
Kim HY, Lampertico P, Nam JY, Lee HC, Kim SU, Sinn DH, Seo YS, Lee HA, Park SY, Lim YS, Jang ES, Yoon EL, Kim HS, Kim SE, Ahn SB, Shim JJ, Jeong SW, Jung YJ, Sohn JH, Cho YK, Jun DW, Dalekos GN, Idilman R, Sypsa V, Berg T, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Janssen HLA, Jang MJ, Lee YB, Kim YJ, Yoon JH, Papatheodoridis GV, Lee JH.
J Hepatol. 2022 Feb; 76(2)

Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study.
Mak LY, Hoang J, Jun DW, Chen CH, Peng CY, Yeh ML, Kim SE, Huang DQ, Jeong JY, Yoon E, Oh H, Tsai PC, Huang CF, Ahn SB, Trinh H, Xie Q, Wong GLH, Enomoto M, Shim JJ, Lee DH, Liu L, Kozuka R, Cho YK, Jeong SW, Kim HS, Trinh L, Dao A, Huang R, Hui RW, Tsui V, Quek S, Khine H, Ogawa E, Dai CY, Huang JF, Cheung R, Wu C, Chuang WL, Lim SG, Yu ML, Yuen MF, Nguyen MH.
Hepatol Int. 2022 Feb; 16(1)

On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients.
Huang CF, Jang TY, Jun DW, Ahn SB, An J, Enomoto M, Takahashi H, Ogawa E, Yoon E, Jeong SW, Shim JJ, Jeong JY, Kim SE, Oh H, Kim HS, Cho YK, Kozuka R, Inoue K, Cheung KS, Mak LY, Huang JF, Dai CY, Yuen MF, Nguyen MH, Yu ML.
Liver Int. 2022 Jan; 42(1)

Relationship between gut microbiome diversity and hepatitis B viral load in patients with chronic hepatitis B.
Joo EJ, Cheong HS, Kwon MJ, Sohn W, Kim HN, Cho YK.
Gut Pathog. 2021 Oct 30; 13(1)

Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial.
Song DS, Kim W, Ahn SH, Yim HJ, Jang JY, Kweon YO, Cho YK, Kim YJ, Hong GY, Kim DJ, Jung YK, Sohn JH, Lee JW, Park SJ, Lee BS, Kim JH, Kim HS, Yoon SK, Kim MY, Lee KS, Lim YS, Lee WS, Yang JM, Kim KH, Han KH, Um SH.
Clin Mol Hepatol. 2021 Apr; 27(2)

Twelve-month post-treatment parameters are superior in predicting hepatocellular carcinoma in patients with chronic hepatitis B.
Ahn SB, Choi J, Jun DW, Oh H, Yoon EL, Kim HS, Jeong SW, Kim SE, Shim JJ, Cho YK, Lee HY, Han SW, Nguyen MH, cohort S.
Liver Int. 2021 Jul; 41(7)

Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients.
Liu M, Tseng TC, Jun DW, Yeh ML, Trinh H, Wong GLH, Chen CH, Peng CY, Kim SE, Oh H, Kwak MS, Cheung M, Toyoda H, Hsu YC, Jeong JY, Yoon EL, Ungtrakul T, Zhang J, Xie Q, Ahn SB, Enomoto M, Shim JJ, Cunningham C, Jeong SW, Cho YK, Ogawa E, Huang R, Lee DH, Takahashi H, Tsai PC, Huang CF, Dai CY, Tseng CH, Yasuda S, Kozuka R, Li J, Wong C, Wong CC, Zhao C, Hoang J, Eguchi Y, Wu C, Tanaka Y, Gane E, Tanwandee T, Cheung R, Yuen MF, Lee HS, Yu ML, Kao JH, Yang HI, Nguyen MH.
Hepatol Int. 2021 Feb; 15(1)

Liver Fibrosis in Asians With Metabolic Dysfunction-Associated Fatty Liver Disease.
Sohn W, Kwon HJ, Chang Y, Ryu S, Cho YK.
Clin Gastroenterol Hepatol. 2021 Jul 3


KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease.
Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL).
Clin Mol Hepatol. 2021 Jul;27(3)


Fasting Ketonuria and the Risk of Incident Nonalcoholic Fatty Liver Disease With and Without Liver Fibrosis in Nondiabetic Adults.
Kim Y, Chang Y, Kwon MJ, Hong YS, Kim MK, Sohn W, Cho YK, Shin H, Wild SH, Byrne CD, Ryu S.
Am J Gastroenterol. 2021 Jun 11


Effect of acute kidney injury on the patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Sohn W, Ham CB, Kim NH, Kim HJ, Cho YK, Jeon WK, Kim BI.
Plos One. 2020 Dec; 15(12)

No Difference in Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection Treated With Entecavir vs Tenofovir.
Oh H, Yoon EL, Jun DW, Ahn SB, Lee HY, Jeong JY, Kim HS, Jeong SW, Kim SE, Shim JJ, Sohn JH, Cho YK, Long-Term Safety of Entecavir Tenofovir in Patients With Treatment-Naive Chronic Hepatitis BVIS.
Clin Gastroenterol Hepatol. 2020 Nov; 18(12)

The effect of moderate alcohol drinking in nonalcoholic fatty liver disease.
Choi JH, Sohn W, Cho YK. Clin Mol Hepatol. 2020 Oct;26(4)

Serum zinc level and hepatic fibrosis in patients with nonalcoholic fatty liver disease.
Kim MC, Lee JI, Kim JH, Kim HJ, Cho YK, Jeon WK, Kim BI, Sohn W.
PLoS One. 2020 Oct 23;15(10)

Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial.
Yim HJ, Kim W, Ahn SH, Yang JM, Jang JY, Kweon YO, Cho YK, Kim YJ, Hong GY, Kim DJ, Jung YK, Um SH, Sohn JH, Lee JW, Park SJ, Lee BS, Kim JH, Kim HS, Yoon SK, Kim MY, Lee KS, Lim YS, Lee WS, Han KH.
Am J Gastroenterol. 2020 Aug; 115(8)


Low Levels of Alcohol Consumption, Obesity, and Development of Fatty Liver With and Without Evidence of Advanced Fibrosis.
Chang Y, Ryu S, Kim Y, Cho YK, Sung E, Kim HN, Ahn J, Jung HS, Yun KE, Kim S, Sung KC, Sohn CI, Shin H, Wild SH, Byrne CD. Hepatology. 2020 Mar;71(3)


Metabolically healthy versus unhealthy obesity and risk of fibrosis progression in non-alcoholic fatty liver disease.
Kim Y, Chang Y, Cho YK, Ahn J, Shin H, Ryu S. Liver Int. 2019 Oct;39(10)


Alcoholic and Nonalcoholic Fatty Liver Disease and Incident Hospitalization for Liver and Cardiovascular Diseases.
Chang Y, Cho J, Cho YK, Cho A, Hong YS, Zhao D, Ahn J, Sohn CI, Shin H, Guallar E,
Ryu S. Clin Gastroenterol Hepatol. 2020 Jan;18(1)


Cardiovascular Health Metrics in the Development and Regression of Nonalcoholic Fatty Liver Disease: A Cohort Study.
Jang EH, Chang Y, Ryu S, Kim S, Kim YH, Sung KC, Cho YK, Lee SJ, Shin H, Wild SH, Byrne CD.
J Clin Med. 2019 May 6;8(5)


Alcoholic and Nonalcoholic Fatty Liver Disease and Liver-Related Mortality: A Cohort Study.
Chang Y, Cho YK, Cho J, Jung HS, Yun KE, Ahn J, Sohn CI, Shin H, Ryu S.
Am J Gastroenterol. 2019 Apr;114(4)


Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study.
Chang Y, Ryu S, Sung KC, Cho YK, Sung E, Kim HN, Jung HS, Yun KE, Ahn J, Shin H, Wild SH, Byrne CD. Gut. 2019 Sep;68(9)


Smoking and the Risk of Non-Alcoholic Fatty Liver Disease: A Cohort Study.
Jung HS, Chang Y, Kwon MJ, Sung E, Yun KE, Cho YK, Shin H, Ryu S.
Am J Gastroenterol. 2019 Mar;114(3)


Nonheavy Drinking and Worsening of Noninvasive Fibrosis Markers in Nonalcoholic Fatty Liver Disease: A Cohort Study.
Chang Y, Cho YK, Kim Y, Sung E, Ahn J, Jung HS, Yun KE, Shin H, Ryu S.
Hepatology. 2019 Jan;69(1)


Kim Y, Chang Y, Cho YK, Ahn J, Shin H, Ryu S. Obesity and Weight Gain Are
Associated With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver
Disease. Clin Gastroenterol Hepatol. 2019 Feb;17(3)


Chang Y, Cho YK, Cho J, Jung HS, Yun KE, Ahn J, Sohn CI, Shin H, Ryu S.
Alcoholic and Nonalcoholic Fatty Liver Disease and Liver-Related Mortality: A
Cohort Study. Am J Gastroenterol. 2019 Jan 23.


Jung HS, Chang Y, Kwon MJ, Sung E, Yun KE, Cho YK, Shin H, Ryu S. Smoking and
the Risk of Non-Alcoholic Fatty Liver Disease: A Cohort Study. Am J
Gastroenterol. 2019 Jan 11.


Chang Y, Cho YK, Kim Y, Sung E, Ahn J, Jung HS, Yun KE, Shin H, Ryu S.
Nonheavy Drinking and Worsening of Noninvasive Fibrosis Markers in Nonalcoholic
Fatty Liver Disease: A Cohort Study. Hepatology. 2019 Jan;69(1):64-75.


Chang Y, Ryu S, Sung KC, Cho YK, Sung E, Kim HN, Jung HS, Yun KE, Ahn J, Shin
H, Wild SH, Byrne CD. Alcoholic and non-alcoholic fatty liver disease and
associations with coronary artery calcification: evidence from the Kangbuk
Samsung Health Study. Gut. 2018 Nov 24.


Chang Y, Noh YH, Suh BS, Kim Y, Sung E, Jung HS, Kim CW, Kwon MJ, Yun KE, Noh
JW, Shin H, Cho YK, Ryu S. Bidirectional Association between Nonalcoholic Fatty
Liver Disease and Gallstone Disease: A Cohort Study. J Clin Med. 2018 Nov
21;7(11).


Cho YK. Combination of synbiotic and sitagliptin in nonalcoholic fatty liver
disease: Is it better than sitagliptin alone? Clin Mol Hepatol. 2018
Sep;24(3):299-301.


Cho YK, Kang YM, Yoo JH, Lee J, Lee SE, Yang DH, Kang JW, Park JY, Jung CH,
Kim HK, Lee WJ. The impact of non-alcoholic fatty liver disease and metabolic
syndrome on the progression of coronary artery calcification. Sci Rep. 2018 Aug
13;8(1)


Yoo JJ, Kim W, Kim MY, Jun DW, Kim SG, Yeon JE, Lee JW, Cho YK, Park SH, Sohn
JH; Korean Association for the Study of the Liver (KASL)-Korea Nonalcoholic fatty
liver Study Group (KNSG). Recent research trends and updates on nonalcoholic
fatty liver disease. Clin Mol Hepatol. 2018 Aug 8


Jang EC, Jun DW, Lee SM, Cho YK, Ahn SB. Comparison of efficacy of
low-carbohydrate and low-fat diet education programs in non-alcoholic fatty liver
disease: A randomized controlled study. Hepatol Res. 2018 Feb;48(3)


Kwak JH, Jun DW, Lee SM, Cho YK, Lee KN, Lee HL, Lee OY, Choi HS, Yoon BC.
Lifestyle predictors of obese and non-obese patients with nonalcoholic fatty
liver disease: A cross-sectional study. Clin Nutr. 2018 Oct;37(5)


Kim NH, Jung YS, Hong HP, Park JH, Kim HJ, Park DI, Cho YK, Sohn CI, Jeon WK,
Kim BI. Association between cotinine-verified smoking status and risk of
nonalcoholic fatty liver disease. Liver Int. 2018 Aug


Yang HJ, Chang Y, Park SK, Jung YS, Park JH, Park DI, Cho YK, Ryu S, Sohn CI.
Nonalcoholic Fatty Liver Disease Is Associated with Increased Risk of Reflux
Esophagitis. Dig Dis Sci. 2017 Dec;62(12)


Kim HS, Cho YK. [Cardiovascular Risk in Patients with Non-alcoholic Fatty
Liver Disease]. Korean J Gastroenterol. 2017 Jun 25;69(6)


Jun DW, Kim SG, Park SH, Jin SY, Lee JS, Lee JW, Kim MY, Choi DH, Cho YK,
Yeon JE, Sohn JH; Korean NAFLD study group (KNSG). External validation of the
non-alcoholic fatty liver disease fibrosis score for assessing advanced fibrosis
in Korean patients. J Gastroenterol Hepatol. 2017 May;32(5


Lee SM, Jun DW, Cho YK, Jang KS. Vitamin D deficiency in non-alcoholic fatty
liver disease: The chicken or the egg? Clin Nutr. 2017 Feb;36(1)


Lee KW, Bang KB, Rhee EJ, Kwon HJ, Lee MY, Cho YK. Impact of hypothyroidism
on the development of non-alcoholic fatty liver disease: A 4-year retrospective
cohort study. Clin Mol Hepatol. 2015 Dec;21(4


Tumor Necrosis Factor­α as a Predictor for the Development of Nonalcoholic Fatty Liver Disease: A 4­Year Follow­Up Study.
Endocrinol Metab (Seoul). 2013 Mar;28(1):41­5.


Regional prevalence of non­alcoholic fatty liver disease in Seoul and Gyeonggi­do, Korea.
Clin Mol Hepatol. 2013 Sep;19(3):266­72


Elevated red cell distribution width is associated with advanced fibrosis in NAFLD.
Clin Mol Hepatol. 2013 Sep;19(3):258­65


The influence of waist circumference on insulin resistance and nonalcoholic fatty liver disease in apparently healthy Korean adults.
Clin Mol Hepatol. 2013 Jun;19(2):140­7.


Apolipoprotein B/AI ratio is independently associated with non­alcoholic fatty liver disease in nondiabetic subjects.
J Gastroenterol Hepatol. 2013 Apr;28(4):678­83.


Enhanced A­FABP expression in visceral fat: potential contributor to the progression of NASH.
Clin Mol Hepatol. 2012 Sep;18(3):279­86


Effect of nonalcoholic Fatty liver disease on the development of type 2 diabetes in nonobese, nondiabetic korean men.
Chon CW, Kim BS, Cho YK, Sung KC, Bae JC, Kim TW, Won HS, Joo KJ.
Gut Liver. 2012 Jul;6(3):368­73


Revision and on clinical practice guideline for liver cirrhosis.
Korean J Hepatol. 2012 Mar;18(1):1­21.


Which metabolic syndrome criteria best predict the presence of non­alcoholic fatty liver disease?
Diabetes Res Clin Pract. 2012 Jan;95(1):19­24.


Serum adipocyte­specific fatty acid­binding protein is associated with nonalcoholic fatty liver disease in apparently healthy subjects.
Journal of Nutritional Biochemistry 22 (2011) 289­292


DNA methylation­dependent regulation of TrkA, TrkB, and TrkC genes in human hepatocellular carcinoma.
Biochemical and Biophysical Research Communications 406 (2011) 89~95


Impact of non­alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes.
Intern Med J. 2010 Jun;40(6):437­42.


Change of insulin sensitivity in hepatitis C patients with normal insulin sensitivity; a 5­year prospective follow­up study variation of insulin sensitivity in HCV patients. Intern Med J. 2010 Jul;40(7):503­11.


Relationship of non­alcoholic fatty liver disease to colorectal adenomatous polyps.
J Gastroenterol Hepatol. 2010 Mar;25(3):562­7.


Serum Uric Acid as a Predictor for the Development of Nonalcoholic Fatty Liver Disease in Apparently Healthy Subjects: A 5­Year Retrospective Cohort Study. Gut and Liver, Vol. 4, No. 3, September 2010, pp. 378­383


Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects.
Am J Gastroenterol. 2010 Nov;105(11):2389­95


Hepatic steatosis and fbrosis in young men with treatment­na？ve chronic hepatitis B.
Liver international 2009/01/22 29(6) 878­883


Abnormal glucose tolerance in young male patients with nonalcoholic fatty liver disease. Liver international 2009 Apr; 9(4) 525­~529


Impact of NAFLD on microalbuminuria in patients with prediabetes and diabetes.
Intern Med J. 2009 May 8.


Deleterious effects of silymarin on the expression of genes controlling endothelial nitric oxide synthase activity in carbon tetrachloride­treated rat livers. Life Sci. 2009 Jun 13.


The Change of Insulin Sensitivity in Hepatitis C Patients with Normal Insulin Sensitivity; A 5­year prospective follow­up study.
Intern Med J. 2009 Aug 27.


Pre­operative predictive factors for gallbladder cholesterol polyps using conventional diagnostic imaging.
World Journal of Gastroenterology 2008 Nov 28; 14(44) 6831~6834


Significance of Palliative Gastrojejunostomy for Unresectable Pancreatic Head Carcinoma. Hepato­Gastroenterology 2008; 55:254­257


The hemostatic effect of endoscopic sodium hyaluronate injection in peptic ulcer bleeding.
Hepato­gastroenterology 2007 Jun 54(76)1276~1279


Factors affecting the serum levels of adipokines in Korean male patients with nonalcoholic fatty liver disease.
Hepato­gastroenterology. 2007 Jul­Aug 54(77) 1512～1516


Relationships Between Estimates of Adiposity, Insulin Resistance, and Nonalcoholic Fatty Liver Disease in a Large Group of Nondiabetic Korean Adults.
Diabetes Care 2007 Aug 30(8) 2113­8


The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease.
Metabolism. 2006 Dec;55(12):1604­9.



[국내]

Non­alcoholic fatty Liver disease in metabolic syndrome
대한당뇨병학회 | 대한당뇨병학회 학술대회자료집 | [2011년]


간성 당뇨병
대한간학회 | 대한간학회지 | [2011년]


Symposium: 비알콜성 지방간 및 지방간염 :
비알코올성 지방간질환의 병발질환 및 대사이상
대한간학회 | 대한간학회지 | [2010년]


특집 : 비알코올성 지방간질환의 병발 질환
대한내과학회 | 대한내과학회지 | [2010년]


전당뇨병 환자에서 ApoB/ApoA­1 Ratio와 비알코올성 지방간과의 연관성
대한내과학회 | 대한내과학회지 | [2010년]


비알코올성 지방간이 다른 내과질환에 미치는 임상적 영향
대한내과학회 | 대한내과학회지 | [2009년]


2008년 유럽간학회 하이라이트 : 간경변증 관련 분야 (정맥류출혈 및 문맥압항진증)
대한간학회 | 대한간학회지 | [2008년]


비알코올간질환과 비만 : 비알코올지방간의 병태생리
대한간학회 | 대한간학회지 | [2008년]


복부비만을 가진 한국인의 내장지방세포에서 Adipokine 발현이 비알코올지방간질환의 진행정도에 미치는 영향
대한간학회 | 대한간학회지 | [2008년]


체내 철 저장상태와 비알코올 지방간 발생과의 연관성
대한내과학회지 2007년 12월 73(6) 587­595


한국 남성 비알코올성 지방간에서 혈청 adipokine 농도 변화에 영향을 미치는 요인
대한내과학회지 (대한내과학회) 2006.7 71권 1호 (58 ~66)


비알코올성 지방간의 중증도에 따른 혈중 Ghrelin 농도 변화
대한내과학회지 (대한내과학회) 2006. 7 71권 1호 (45~51)


만성 B형 간염환자에서라미부딘 치료 후(NO) 대사체 농도의 감소
대한내과학회지 (대한내과학회) 2006. 470권 4호 (511~517)


비알코올성지방간을 가진 한국 남성에서 ALT 증가와 혈중 adiponectin치의 연관성
대한간학회지 (대한간학회) 2006. 6 12권 2호 (221~229)

기타

닥터스토리
  • 정보보호관리체계(ISMS) 인증
  • 국제정보보호(ISO27001) 인증
  • 보건복지부
    의료기관 인증병원
  • 생명의학연구윤리 국제인증 획득
  • 美, 하원 표창장
  • 美, 존스홉킨스
    연구협약 체결